AEGLEA BIOTHERAPEUTICS RAISED $44 MILLION

What does Aeglea Biotherapeutics do?

Aeglea Biotherapeutics Holdings Inc. is a cutting edge contemporary biopharmaceutical company developing novel treatment methodologies for metabolic disorders by engineering enzymes that target these specific metabolic disorders, which are a result of tumors producing the amino acids in excess.

The state of the art engineered enzymes precisely target the malignant tumors producing amino acids in exorbitance and by breaking these amino acids the problem of the specific metabolic disorder is duly addressed.

By developing these innovative enzymes that target the amino acids produced by tumors, Aeglea Biotherapeutics has emerged to be a serious player in the field of oncology and has brought light at the end of the tunnel for millions of patients suffering from carcinomas.

How much Aeglea Biotherapeutics was funded?

Aeglea Biotherapeutics has raised around $44 million in a most recent spate of Series B funding on the 23^rd march 2015 by their investors Novartis venture fund and Lilly ventures.

Previous rounds of funding:

The company has received around $12 million from KBI Biopharma and featuring Lilly ventures once again in this Series A funding on February 6^th 2015.

There was a history of $12 million funding on January 9^th the previous year to Series A funding by ATX Tech incubator.

What is next for Aeglea Biotherapeutics?

With this new round of funding expected to give a spring in their stride that helps the company targeting their energies more towards the unchartered territory of reaching new avenues in the much needed oncology research and thereby helping millions in need.

More about Aeglea Biotherapeutics:

George Georgiou of University of Texas was the pioneer that engineered the human enzymes back in 2013.

Of the several lives saving enzymes developed Aeglea Biotherapeutics the most prominent ones are AEB4104 for the degradation of homocysteine to be potentially used for treating homocysteinuria.

AEB 1102 is expected to treat Hyperargininuria and other malignancies.

Aeglea Biotherapeutics is believed to become a top-notch provider of oncological treatment that provides revolutionary and radical treatment of the dreadful metabolic disorders.